Menu


Selected Abstracts > CHF

Title: Advances in the treatment of heart failure with a preserved ejection fraction

Introduction :Over the last several years it has become increasingly apparent that many patients with heart failure (HF) have a normal or nearly normal ejection fraction (EF) - described as heart failure with preserved ejection fraction (HF-PEF). Epidemiological studies [1-5]...


Introduction :Over the last several years it has become increasingly apparent that many patients with heart failure (HF) have a normal or nearly normal ejection fraction (EF) - described as heart failure with preserved ejection fraction (HF-PEF). Epidemiological studies [1-5] and patient registries have reported a prevalence of up to 40-71% of patients with HF. A recent study [6_] from Olmstead County found that the prevalence of HF-PEF among patients with a discharge diagnosis of HF increased significantly from 1987 to 2001. The prevalence of this condition will likely keep increasing as the prevalence of elderly people with comorbid conditions such as hypertension, diabetes, obesity, and coronary artery disease increases. Although the rates of mortality and morbidity associated with HF-PEF and compared with HF due to depressed EF have varied, there is consensus that HF-PEF is a condition associated with substantial morbidity and mortality. The occurrence of clinical events increases markedly once patients are hospitalized for HF. A recent review [1] suggests that, once hospitalized for HF, patients with HF-PEF have a high rate of rehospitalization; up to a third may be readmitted for HF exacerbation within a year and about 45-60% may be hospitalized by 1 year for any reason. Similarly, once hospitalized, the mortality may be as high as _22-29% at 1 year and _65% at 5 years [6_,7_]. A study [6_] examining secular trends of HF within the Olmstead County found that, although survival improved significantly over time among patients with reduced EF, there was no trend toward improvement among patients with HF-PEF. Thus, there exists an urgent need to develop effective treatment strategies for patients with HF-PEF